Success Metrics

Completion Rate

0%(0/2)

Active Trials

1(33%)

Terminated

2(67%)

Phase Distribution

Ph phase_2

33%

Ph phase_3

33%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Terminated(2)

Detailed Status

Terminated2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 31 (33.3%)

Trials by Status

terminated267%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_1

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

NCT05200442

terminatedphase_3

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

NCT02740114

terminatedphase_2

Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter

NCT01900730

Clinical Trials (3)

Showing 3 of 3 trials

NCT05200442Phase 1

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Recruiting

NCT02740114Phase 3

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

Terminated

NCT01900730Phase 2

Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter

Terminated

All 3 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 3